Olaparib & BevacizumabTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Sponsor:

NRG Oncology

Code:

NCT06580314

Conditions

Fallopian Tube Endometrioid Adenocarcinoma

Fallopian Tube High Grade Serous Adenocarcinoma

Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor

FIGO Stage III Ovarian Cancer 2014

FIGO Stage IV Ovarian Cancer 2014

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bevacizumab

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

Olaparib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by NRG Oncology on 2026-08-07.